Materialise NV will convene an extraordinary shareholders’ meeting on November 14, 2025, at 17:00 CET at its registered office in Leuven, Belgium, with a digital execution by a notary in Ghent.
The agenda includes proposals to move share capital, authorize a potential buyback program of up to €30 million in American Depositary Shares, amend the articles of association to introduce double voting rights for certain shares, adopt a new text of the articles, approve the remuneration policy, confirm the board composition, and mandate the statutory auditor for sustainability assurance.
The meeting follows the company’s recent Q3 2025 financial results, which showed a 3.5 % year‑over‑year decline in total revenue to €66.3 million, a 10.3 % increase in the Medical segment, and a stable gross profit margin of 56.8 %. Management highlighted cost‑control measures and continued investment in research and development.
Materialise is also pursuing a dual listing of its ordinary shares on Euronext Brussels in addition to its Nasdaq listing of ADSs. The proposed buyback program is contingent on shareholder approval at the meeting and the completion of the Brussels listing, with repurchases expected to begin in January 2026.
The proposed amendments to the articles, including double voting rights, are intended to strengthen long‑term shareholder influence and support the company’s strategy to enhance shareholder value, provide liquidity options, and potentially access additional capital in the future.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.